Cite
HARVARD Citation
Peng, Z. et al. (2021). Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study. Cancer communications. 41 (11), pp. 1173-1182. [Online].